Bristol-myers Squibb Stock News

These 2 Fast-Growing REITs Win Despite Inflation

Bristol Myers Squibb (BMY) closed at $68.77 in the latest trading session, marking a -0.85% move from the prior day.

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Bristol Myers' (BMY) immuno-oncology Opdivo gets FDA nod for adult patients with resectable non-small cell lung cancer in the neoadjuvant setting in combination with platinum-doublet chemotherapy.

Do Food and Drug Administration decisions—thumbs up or thumbs down—affect the stock prices of companies seeking drug approvals? We're likely to find out this month as several key drugs are about t

DUBLIN--(BUSINESS WIRE)--The "Investigation Report on China''s Dasatinib Market 2021-2025" report has been added to ResearchAndMarkets.com''s offering. Dasatinib, developed by Bristol-Myers Squibb, is an anti-tumor drug. It was first approved by the FDA in 2006 for the treatment of adult patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in the chronic and accelerated phases that are resistant or intolerant to previous treatment with imatinib. In 2011, Dasatinib w

Teva Pharmaceuticals (TEVA) has launched the first generic version of Bristol-Myers Squibb''s (BMY) Revlimid (lenalidomide) for multiple myeloma and several types of leukemia.

The FDA has approved Bristol Myers Squibb Co''s (NYSE: BMY ) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for resectable non-small cell lung cancer (NSCLC) in the neoadjuvant setting. The agency approved the Opdivo combo just five … Full story available on Benzinga.com

Bristol-Myers Squibb ( BMY , Financial) seems to be on track for a solid year in 2022, fueled by strong sales of core drugs Eliquis and Opdivo, as well as continued demand growth for their new product

The approval was based on data from a late-stage study showing the drug along with chemotherapy improved event-free survival and pathologic complete response compared to chemotherapy alone in patients with resectable non-small cell lung cancer The post US FDA approves expanded use of Bristol Myers cancer drug Opdivo appeared first on Express Pharma .

The U.S. Food and Drug Administration ((FDA)) approved Bristol Myers Squibb'' (BMY) Opdivo (nivolumab) in combination with platinum-doublet chemotherapy for adult patients with…

Can these health care stocks climb this month?

Investors need to pay close attention to Bristol-Myers (BMY) stock based on the movements in the options market lately.

Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca. Major companies in the pharmaceuticals market include Johnson & Johnson, Novartis AG, Bristol-Myers Squibb, AbbVie, Sanofi S. A, Pfizer Inc. , GlaxosmithKline, F. Hoffmann-La Roche Ltd. , Merck & Co. and AstraZeneca.

A whale with a lot of money to spend has taken a noticeably bullish stance on Bristol-Myers Squibb . Looking at options history for Bristol-Myers Squibb (NYSE: BMY ) we detected 11 strange trades. If we consider the specifics of each trade, it is accurate to state that 72% of the investors opened trades with bullish expectations and 27% with bearish. From the overall spotted trades, 3 are puts, for a total amount of $159,719 and 8, calls, for a total amount of $1,123,867. What''s The Price Target? Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $72.5 for Bristol-Myers Squibb … Full story available on Benzinga.com